Abstract:Purpose: Neurofibromatosis type 1(NF1) and type 2(NF2) are both autosomal dominantly inherited disorders and originate from schwann cells. This study was done to investigate the genetic and proteomic profiles of the tumours.Methods: Mutational analyses of neurofibromatosis type 1 and type 2 genes (NF1 and NF2) in 15 NF1 and NF2 patients were carried out using Sanger sequencing. TMT-labeled spectrometry analysis was used to identify the proteome of neurofibromatosis type 1 and type 2 relative to nerve controls. Loss of heterozygosity were analysed for the candidate gene EPB41L3. Protein expression of tumour tissues/cultures was assessed by Western blots and/or immunofluorescence.Finds: DNA sequencing showed frequent mutations within NF1 or NF2 in the neurofibromatosis type 1 and type 2, respectively. 159 proteins were significantly differentially expressed in NF1 compared with normal nerves, and 180 proteins were significantly differentially expressed in NF2 compared with normal nerves. Among these, 11 were found commonly up-regulated and 30 down-regulated in both tumors. Among the commonly significantly down-regulated proteins in both tumors we consistently find EPB41L3.The EPB41L3 tumour suppressor showed the most significantly decreased expression, and existed predominantly at the cytoplasm of HEI193 and NF1 cell cultures. Western blot analysis identified the down-regulation in the NF1 and NF2 association with neurofibromin and merlin, respectively. LOH of EPB41L3 was more common among neurofibromatosis type 1(seen in 3 of 5 tumors, 60%) and least common among neurofibromatosis type 2 (2 of 10, 20%).Interpretation: Our data first get an insight into the common molecular mechanisms of neurofibroma, that indicates the potential role of EPB41L3 as a therapeutic target for this tumor syndrome.Funding Information: This work was supported by the National Natural Science Foundation of China (Grant No. 82171366 to Wei Chen; No. 82070541, 81600625, both to ML; 81771332, 81571184, both to CZ; 82172820 to JZ).and Grant No. 19ZR1447400 to Wei Chen. Jiangxi province outstanding poject (Grant No.20202ACBL216005 to Wei Chen); the Health Industry Clinical Research Project of Shanghai Municipal Health Commission (No. 20204125, to ML; No. 201840110, to SX); the Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (No. PWR12018-07, to CZ);the Key Discipline Construction Project of Pudong Health Bureau of Shanghai (No. PWZxk2017-23, to CZ); the Top-level Clinical Discipline Project of Shanghai Pudong (No. PWYgf2018-05, to CZ) .Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: Informed written consent was obtained from all patients donating tissue. This study was approved by the Institutional Review Board of the ethics committee of The shanghai east Hospital affiliated to School of Medicine, Shanghai Tong Ji University.

Integrated Analysis of Transcriptome and Differential Methylation of Neurofibromatosis Type 2 Vestibular Schwannomas

Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis

Identification of Key Pathways and Genes in Vestibular Schwannoma Using Bioinformatics Analysis.

Identification of Key Biomarkers and Immune Infiltration in Sporadic Vestibular Schwannoma Basing Transcriptome-Wide Profiling

Comprehensive Bioinformatics Analysis of Lncrna Regulation and Screening for Pathogenic Genes in NF2-related Schwannomatosis

Identification of Differentially Expressed miRNAs and mRNAs in Vestibular Schwannoma by Integrated Analysis.

Csig-19. Identification And Targeting Of Tumor Driver Schwann(Nf2Loss) Cells In Sporadic And Nf2-Related Vestibular Schwannomas

Gene expression profiles between cystic and solid vestibular schwannoma indicate susceptible molecules and pathways in the cystic formation of vestibular schwannoma

Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis

Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma

Proteomic and Genetic Analysis Reveals Loss of EPB41L3 Related to the Tumorigenesis of Neurofibromatosis Type 1 and Type 2

Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis

A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma

Mutation Analysis of NF2 Gene and Clinical Investigation in a Chinese Family with Neurofibromatosis Type II

Single-Cell RNA-Seq Reveals Heterogeneity of Cell Communications between Schwann Cells and Fibroblasts within Vestibular Schwannoma Microenvironment

Mutation spectrum and differential gene expression in cystic and solid vestibular schwannoma

Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and Its Prognostic Impact on Tumour Growth Patterns

Identification Of Predictive Proteins And Biological Pathways For The Tumorigenicity Of Vestibular Schwannoma By Proteomic Profiling

Individualized Diagnosis and Treatment of Neurofibromatosis Type Ⅱ Guided by Molecular Genetic Analysis

Single-cell Transcriptomes Reveal the Heterogeneity and Microenvironment of Vestibular Schwannoma.

Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Screening in NF2-associated Schwannoma.